A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults patients, \>/=18 years of age
Chronic Hepatitis C, Genotype 1 and 4
HCV RNA \>/=50,000 IU/mL
treatment-naive
You may not be if
Patients with cirrhosis or incomplete/transition to cirrhosis
Patients with other forms of liver disease, HIV infection, hepatocellular carcinoma or severe cardiac disease
Clareo Health | A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
